Eledon Pharmaceuticals, Inc.
NCM: ELDNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Eledon Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ELDN Z-Score →About Eledon Pharmaceuticals, Inc.
Healthcare
Biotechnology
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
📊 Fundamental Analysis
Eledon Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -35.8%, which indicates that capital utilization is currently under pressure.
At a current price of $3.10, ELDN currently sits at the 54th percentile of its 52-week range (Range: $1.35 - $4.60).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$246.85M
Trailing P/E
--
Forward P/E
-3.86
Beta (5Y)
0.84
52W High
$4.60
52W Low
$1.35
Avg Volume
1.05M
Day High
Day Low